Orphan Drugs Market Size, Share, Growth and Industry Report 2024-2031

Orphan Drugs Market Size, Share, Industry, Forecast and outlook (2024-2031)

<h2>Orphan Drugs Market is segmented By Product Type (Biological, Non-Biological), By Therapy Area (Oncology, Hematology Diseases, Central Nervous System, Cardiovascular, Endocrine, Respiratory,&nbsp;Immunomodulators,&nbsp;Gastro-Intestinal,&nbsp;Musculoskeletal,&nbsp;Systemic Anti-Infectives,&nbsp;Dermatology, Others), By Distribution Channel (Hospital Pharmacies,&nbsp; Retail Pharmacies, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2024-2031</h2>

&nbsp;

<h3>Orphan Drugs Market Overview</h3>

<blockquote>
The Global Orphan Drugs Market is estimated to reach at a CAGR of 11.2% during the forecast period (2024-2031).&nbsp;
</blockquote>

Life-threatening or persistently disabling diseases are treated, prevented from occurring, or diagnosed with an orphan drug. It is mostly used to treat rare disorders. Less than 200,000 Americans and five out of every 10,000 people in the European Union are affected by this rare sickness or condition.

&nbsp;

<h3>Orphan Drugs Market Scope</h3>

<table border="1" cellpadding="1" cellspacing="1">
	<tbody>
		<tr>
			<td>
			Metrics
			</td>
			<td>
			Details
			</td>
		</tr>
		<tr>
			<td>
			Market&nbsp;CAGR
			</td>
			<td>
			11.2%
			</td>
		</tr>
		<tr>
			<td>
			Segments Covered
			</td>
			<td>
			By Product Type,&nbsp;By Therapy Area,&nbsp;By Distribution Channel,&nbsp;and By Region
			</td>
		</tr>
		<tr>
			<td>
			Report Insights Covered
			</td>
			<td>
			Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
			</td>
		</tr>
		<tr>
			<td>
			Fastest Growing Region
			</td>
			<td>
			Asia Pacific
			</td>
		</tr>
		<tr>
			<td>
			Largest Market Share&nbsp;
			</td>
			<td>
			North America
			</td>
		</tr>
	</tbody>
</table>

&nbsp;

For More Insights <a href="https://www.datamintelligence.com/download-sample/orphan-drugs-market" target="_blank">Request Free Sample</a>

&nbsp;

<h3>Orphan Drugs Market&nbsp;Dynamics</h3>

The rise in research and development activities, rising adoption of orphan drugs for the treatment of diseases, and an increase in the geriatric population will drive the orphan drugs market growth.

The increasing awareness of rare diseases is expected to drive the market growth&nbsp; &nbsp;

The rising awareness of rare diseases and treatment for them is expected to boost the market over the forecast period. As per the article published in Perspective in Clinical Research 2022, regulators like the FDA have recently developed an online platform called the &quot;FDA Rare Disease Photo and Video Project&quot; to record and share staff experiences and real-time patient accounts. By setting up various meetings with patients, caregivers, and FDA employees, the office of patient affairs supports patient-centricity with this goal. Several nonprofit organizations, such as the National Organization for Rare Disorders and the European Organisation for Rare Diseases, support regulatory and research activities in Europe and the United States, respectively, and promote patient advocacy through patient assistance, information sharing, and networking between various patient groups.

Furthermore, per the article published in Institute for Clinical and Economic Review, cell and gene therapies being developed as of 2020 are for rare diseases, and it is predicted that more than 70% of rare diseases are genetic. As of the middle of 2020, the FDA had authorized 599 orphan products since the Orphan Drug Act was passed. The percentage of first-in-class orphan pharmaceuticals is substantially higher than that of nonorphan drugs, with 50% of all orphan drugs authorized in the U.S. Despite the pandemic, overall <a href="https://www.datamintelligence.com/research-report/clinical-trials-market" target="_blank">clinical trial</a> activity has continued because the industry has adjusted to the disruption and created new strategies to support ongoing research. Five thousand five hundred new planned clinical trial launches were reported in 2021, up 14% from 2020 and 19% from 2019.

The difficulty of gathering sufficient efficacy and safety data will hamper the growth of the market 

However, the difficulty of gathering sufficient efficacy and safety data in small groups, the risk of financial support for both developers and healthcare systems, and the limited understanding of most diseases are barriers to developing medical treatments or cures for rare diseases. Governments&#39; actions alone are insufficient to narrow the market gap that arises from each rare disease&#39;s generally low commercial potential. Additionally, deciding on a working definition of what defines a &quot;rare&quot; as opposed to an &quot;ultra-rare&quot; illness would be one of the major obstacles in building a policy platform to stimulate the development of ultra-rare drugs. These elements are limiting further market expansion.

<h3>COVID-19 Impact Analysis on&nbsp;Orphan Drugs Market</h3>

The appearance of COVID-19 considerably impacted the global orphan drugs market. As per the article published in Frontiers in Public Health 2021, there are about five to eight thousand rare diseases, particularly with a genetic basis, affecting approximately 400 million people worldwide. People with rare diseases and their caretakers report significant care insufficiencies and unmet clinical needs. The difficulty and expense of assembling large compatriots of affected individuals for study and conducting research funding is already a problem for researchers. Together with the general anxieties about health concerns everyone else has, people with rare diseases have a double burden of the question due to COVID-19. They also face a supply of medications and the accessibility of essential occupational therapies they need regularly.

On the other hand, with the prevailing COVID-19 pandemic in 2020, the FDA approved 32 orphan-designated drugs and biological products to significantly sustain progress in orphan drug research and development. The Center for Drug Evaluation and Research office created a rare disease hub to assess marketing applications for certain rare diseases. It collaborated with a rare disease team to receive support and assistance for enabling a rare disease policy. FDA launched the orphan drug modernization pilot program to keep pace with the increase in application in subsequent years. The FDA is to review all applications within a stipulated time of 90 days, irrespective of the volume and complexity of the application.

<h3>Orphan Drugs Market Segmentation Analysis</h3>

The oncology segment is expected to grow at the fastest CAGR during the forecast period (2023-2030)&nbsp;&nbsp;&nbsp;&nbsp; 

The oncology segment is expected to boost the market throughout the forecast. In July 2022, The FDA granted orphan drug designation to several therapies in development for oncology indications. MB-106 (Mustang Bio) is a CD20-targeted, autologous chimeric antigen receptor T-cell therapy. The orphan drug designation applies to the use of the agent for the treatment of Waldenstrom macroglobulinemia. Paxalisib (Kazia Therapeutics Limited) is a phosphatidylinositol 3-kinase inhibitor. The designation applies to the agent&#39;s treatment of atypical rhabdoid/teratoid tumors, an aggressive and rare childhood brain cancer. VBI-1901 (VBI Vaccines) is a bivalent gB/pp65 immunotherapeutic vaccine candidate. The designation applies to the use of this agent for the treatment of glioblastoma.

In addition, in January 2021, the U.S. Food and Medication Administration (FDA) granted PVSRIPO (stage IIB-IV) as an orphan drug for the treatment of advanced melanoma by Istari Oncology, Inc. . A patient&#39;s adaptive and innate immune systems are activated by PVSRIPO, a novel viral immunotherapy based on the Sabin type 1 polio vaccine, to promote an anti-tumor response and establish long-term immunologic memory to the prevention of cancer recurrence.

<h3>Orphan Drugs Market Geographical Share</h3>

North America region holds the largest market share of the global orphan drugs market

North America dominates the market for orphan drugs and is expected to show a similar trend over the forecast period. It is anticipated to hold a significant market size over the forecast period (2022-2029) owing to the advanced healthcare system, government initiatives and the presence of many market players. The FDA Office of Orphan Products Development approved orphan drug designation for novel drugs and biologics that are used for the safe and effective treatment, diagnosis and prevention of rare diseases or disorders that suffer fewer than 200,000 people in the United States region. The designation allows key players to qualify for various incentives, including tax credits for qualified clinical trials and, upon regulatory approval, 7 years of market exclusivity. In addition, the U.S. remains the country with the earliest and highest number of launches and among the 72 NASs launched in 2021, a record 44 (over 60%) were characterized by the FDA as first-in-class, and more than half (40) carried an orphan drug designation indicating their use for patients with rare diseases.

Moreover, in September 2020, AbbVie&#39;s experimental therapy for patients with spinal cord injury, elezanumab (ABT-555), was given Orphan drugs and Fast Track designations by the USFDA. A monoclonal antibody of the human immunoglobulin (Ig)G1 isotype called elezanumab binds only to the repellent guidance molecule A (RGMa).

<h3>Orphan Drugs Companies and Competitive Landscape</h3>

The orphan drugs market is a moderately competitive presence of local and global companies. Some of the key players which are contributing to the growth of the market are <a href="https://news.abbvie.com/2020-09-28-AbbVie-Receives-Orphan-Drug-and-Fast-Track-Designations-from-the-U-S-Food-and-Drug-Administration-for-Elezanumab-an-Investigational-Monoclonal-Antibody-RGMa-Inhibitor-for-the-Treatment-of-Spinal-Cord-Injury">AbbVie Inc</a>., Alexion Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Celgene Corporation, Johnson &amp; Johnson, Merck &amp; Co., Inc., <a href="https://www.novartis.com/news/media-library/orphan-medicinal-products-pediatrics">Novartis AG</a>, Roche Holding AG, Sanofi SA, and Shire plc among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, contributing to the expansion of the orphan drugs market globally.

For instance,

<ul>
	<li>In June 2020, Chiasma, Inc. announced that the U.S. Food and Drug Administration (FDA) approved MYCAPSSA (octreotide) capsules for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.</li>
</ul>

AbbVie Inc 

Overview: 

AbbVie is a research-based biopharmaceutical organization founded in 2013 and headquartered in the United States.&nbsp; It is developing innovative and advanced therapies to meet the requirement of complex and serious diseases.

Product Portfolio:

HUMIRA (adalimumab): It is used to reduce symptoms of Moderate to severe rheumatoid arthritis (RA) in adults, Psoriatic arthritis (PsA) in adults, and ulcerative colitis in adults.

&nbsp;

The global orphan drugs market report would provide access to approximately 65+ market data tables, 65+ figures, and in the range of 200+ (approximate) pages.

<ol>
	<li>Market Methodology and Scope
	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>Market Definition and Overview</li>
	<li>Executive Summary
	<ol>
		<li>Market Snippet By Product Type</li>
		<li>Market Snippet By Therapy Area</li>
		<li>Market Snippet By Distribution Channel</li>
		<li>Market Snippet by Region</li>
	</ol>
	</li>
	<li>Market Dynamics
	<ol>
		<li>Market Impacting Factors
		<ol>
			<li>Drivers</li>
			<li>High prevalence of diabetes disease</li>
			<li>Rising research activities</li>
			<li>Restraints:</li>
			<li>High cost of drugs</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>Industry Analysis
	<ol>
		<li>Porter&#39;s Five Forces Analysis</li>
		<li>Supply Chain Analysis</li>
		<li>Regulatory Analysis</li>
		<li>Pricing Analysis</li>
		<li>&nbsp;Unmet Needs</li>
	</ol>
	</li>
	<li>COVID-19 Analysis
	<ol>
		<li>Analysis of Covid-19 on the Market
		<ol>
			<li>Before COVID-19 Market Scenario</li>
			<li>Present COVID-19 Market Scenario</li>
			<li>After COVID-19 or Future Scenario</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid Covid-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During Pandemic</li>
		<li>Manufacturer&rsquo;s Strategic Initiatives</li>
		<li>Conclusion&nbsp;</li>
	</ol>
	</li>
	<li>By Product Type
	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type</li>
			<li>Market Attractiveness Index, By Product Type</li>
		</ol>
		</li>
		<li>Biological*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li>
		</ol>
		</li>
		<li>Non-biological</li>
	</ol>
	</li>
	<li>By Therapy Area
	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Area</li>
			<li>Market Attractiveness Index, By Therapy Area</li>
		</ol>
		</li>
		<li>Oncology*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li>
		</ol>
		</li>
		<li>Hematology Diseases</li>
		<li>Central Nervous System</li>
		<li>Cardiovascular</li>
		<li>Endocrine</li>
		<li>Respiratory</li>
		<li>Immunomodulators</li>
		<li>Gastro-Intestinal</li>
		<li>Musculoskeletal</li>
		<li>Systemic Anti-infectives</li>
		<li>Dermatology</li>
		<li>Others</li>
	</ol>
	</li>
	<li>By Distribution Channel
	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Attractiveness Index, By Distribution Channel</li>
		</ol>
		</li>
		<li>Hospital Pharmacies*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li>
		</ol>
		</li>
		<li>Retail Pharmacies</li>
		<li>Online Pharmacies</li>
	</ol>
	</li>
	<li>By Region
	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Area</li>
			<li>&nbsp;</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>The U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Area</li>
			<li>&nbsp;</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>U.K.</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Area</li>
			<li>&nbsp;</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia Pacific
		<ol>
			<li>Introduction</li>
			<li>&nbsp;Key Region-Specific Dynamics</li>
			<li>&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Area</li>
			<li>&nbsp;</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>Australia</li>
				<li>Rest of Asia Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Area</li>
			<li>&nbsp;</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel&nbsp;</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>Competitive Landscape
	<ol>
		<li>Key Developments and Strategies</li>
		<li>Company Share Analysis</li>
		<li>Treatment type Benchmarking</li>
	</ol>
	</li>
	<li>Company Profiles
	<ol>
		<li>AbbVie Inc.*
		<ol>
			<li>Company Overview</li>
			<li>Treatment type Portfolio and Description</li>
			<li>Key Highlights</li>
			<li>Financial Overview</li>
		</ol>
		</li>
		<li>Alexion Pharmaceuticals, Inc.</li>
		<li>Bristol-Myers Squibb Company</li>
		<li>Celgene Corporation</li>
		<li>Johnson &amp; Johnson</li>
		<li>Merck &amp; Co., Inc.</li>
		<li>Novartis AG</li>
		<li>Roche Holding AG</li>
		<li>Sanofi SA</li>
		<li>Shire plc &nbsp;(*LIST NOT EXHAUSTIVE)</li>
	</ol>
	</li>
	<li>DataM Intelligence
	<ol>
		<li>Appendix</li>
		<li>About Us and Services</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

&nbsp;List of Tables

Table 01 Global Orphan Drugs Market Value, By Product Type, 2023, 2027 &amp; 2031 ($ Million)

Table 02 Global Orphan Drugs Market Value, By Therapy Area, 2023, 2027 &amp; 2031 ($ Million)

Table 03 Global Orphan Drugs Market Value, By Distribution Channel, 2023, 2027 &amp; 2031 ($ Million)

Table 04 Global Orphan Drugs Market Value, By Region, 2023, 2027 &amp; 2031 ($ Million)

Table 05 Global Orphan Drugs Market Value, By Product Type, 2023, 2027 &amp; 2031 ($ Million)

Table 06 Global Orphan Drugs Market Value, By Product Type, 2022-2031 ($ Million)

Table 07 Global Orphan Drugs Market Value, By Therapy Area, 2023, 2027 &amp; 2031 ($ Million)

Table 08 Global Orphan Drugs Market Value, By Therapy Area, 2022-2031 ($ Million)

Table 09 Global Orphan Drugs Market Value, By Distribution Channel, 2023, 2027 &amp; 2031 ($ Million)

Table 10 Global Orphan Drugs Market Value, By Distribution Channel, 2022-2031 ($ Million)

Table 11 Global Orphan Drugs Market Value, By Region, 2023, 2027 &amp; 2031 ($ Million)

Table 12 Global Orphan Drugs Market Value, By Region, 2022-2031 ($ Million)

Table 13 North America Orphan Drugs Market Value, By Product Type, 2022-2031 ($ Million)

Table 14 North America Orphan Drugs Market Value, By Therapy Area, 2022-2031 ($ Million)

Table 15 North America Orphan Drugs Market Value, By Distribution Channel, 2022-2031 ($ Million)

Table 16 North America Orphan Drugs Market Value, By Country, 2022-2031 ($ Million)

Table 17 South America Orphan Drugs Market Value, By Product Type, 2022-2031 ($ Million)

Table 18 South America Orphan Drugs Market Value, By Therapy Area, 2022-2031 ($ Million)

Table 19 South America Orphan Drugs Market Value, By Distribution Channel, 2022-2031 ($ Million)

Table 20 South America Orphan Drugs Market Value, By Country, 2022-2031 ($ Million)

Table 21 Europe Orphan Drugs Market Value, By Product Type, 2022-2031 ($ Million)

Table 22 Europe Orphan Drugs Market Value, By Therapy Area, 2022-2031 ($ Million)

Table 23 Europe Orphan Drugs Market Value, By Distribution Channel, 2022-2031 ($ Million)

Table 24 Europe Orphan Drugs Market Value, By Country, 2022-2031 ($ Million)

Table 25 Asia-Pacific Orphan Drugs Market Value, By Product Type, 2022-2031 ($ Million)

Table 26 Asia-Pacific Orphan Drugs Market Value, By Therapy Area, 2022-2031 ($ Million)

Table 27 Asia-Pacific Orphan Drugs Market Value, By Distribution Channel, 2022-2031 ($ Million)

Table 28 Asia-Pacific Orphan Drugs Market Value, By Country, 2022-2031 ($ Million)

Table 29 Middle East &amp; Africa Orphan Drugs Market Value, By Product Type, 2022-2031 ($ Million)

Table 30 Middle East &amp; Africa Orphan Drugs Market Value, By Therapy Area, 2022-2031 ($ Million)

Table 31 Middle East &amp; Africa Orphan Drugs Market Value, By Distribution Channel, 2022-2031 ($ Million)

Table 32 AbbVie Inc.: Overview

Table 33 AbbVie Inc.: Product Portfolio

Table 34 AbbVie Inc.: Key Developments

Table 35 Alexion Pharmaceuticals, Inc.: Overview

Table 36 Alexion Pharmaceuticals, Inc.: Product Portfolio

Table 37 Alexion Pharmaceuticals, Inc.: Key Developments

Table 38 Bristol-Myers Squibb Company: Overview

Table 39 Bristol-Myers Squibb Company: Product Portfolio

Table 40 Bristol-Myers Squibb Company: Key Developments

Table 41 Celgene Corporation: Overview

Table 42 Celgene Corporation: Product Portfolio

Table 43 Celgene Corporation: Key Developments

Table 44 Johnson &amp; Johnson: Overview

Table 45 Johnson &amp; Johnson: Product Portfolio

Table 46 Johnson &amp; Johnson: Key Developments

Table 47 Merck &amp; Co., Inc.: Overview

Table 48 Merck &amp; Co., Inc.: Product Portfolio

Table 49 Merck &amp; Co., Inc.: Key Developments

Table 50 Novartis AG: Overview

Table 51 Novartis AG: Product Portfolio

Table 52 Novartis AG: Key Developments

Table 53 Roche Holding AG: Overview

Table 54 Roche Holding AG: Product Portfolio

Table 55 Roche Holding AG: Key Developments

Table 56 Sanofi SA: Overview

Table 57 Sanofi SA: Product Portfolio

Table 58 Sanofi SA: Key Developments

Table 59 Shire plc: Overview

Table 60 Shire plc: Product Portfolio

Table 61 Shire plc: Key Developments

List of Figures

Figure 01 Global Orphan Drugs Market Share, By Product Type, 2022 &amp; 2031 (%)

Figure 02 Global Orphan Drugs Market Share, By Therapy Area, 2022 &amp; 2031 (%)

Figure 03 Global Orphan Drugs Market Share, By Distribution Channel, 2022 &amp; 2031 (%)

Figure 04 Global Orphan Drugs Market Share, By Region, 2022 &amp; 2031 (%)

Figure 05 Global Orphan Drugs Market Value, 2022-2031 ($ Million)

Figure 06 Global Orphan Drugs Market Y-o-Y Growth, By Product Type, 2022-2031 (%)

Figure 07 Biological: Global Orphan Drugs Market Value, 2022-2031 ($ Million)

Figure 08 Non-biological: Global Orphan Drugs Market Value, 2022-2031 ($ Million)

Figure 09 Global Orphan Drugs Market Y-o-Y Growth, By Therapy Area, 2022-2031 (%)

Figure 10 Oncology: Global Orphan Drugs Market Value, 2022-2031 ($ Million)

Figure 11 Hematology Diseases: Global Orphan Drugs Market Value, 2022-2031 ($ Million)

Figure 12 Central Nervous System: Global Orphan Drugs Market Value, 2022-2031 ($ Million)

Figure 13 Cardiovascular: Global Orphan Drugs Market Value, 2022-2031 ($ Million)

Figure 14 Endocrine: Global Orphan Drugs Market Value, 2022-2031 ($ Million)

Figure 15 Respiratory: Global Orphan Drugs Market Value, 2022-2031 ($ Million)

Figure 16 Immunomodulators: Global Orphan Drugs Market Value, 2022-2031 ($ Million)

Figure 17 Gastro-Intestinal: Global Orphan Drugs Market Value, 2022-2031 ($ Million)

Figure 18 Musculoskeletal: Global Orphan Drugs Market Value, 2022-2031 ($ Million)

Figure 19 Systemic Anti-infectives: Global Orphan Drugs Market Value, 2022-2031 ($ Million)

Figure 20 Dermatology: Global Orphan Drugs Market Value, 2022-2031 ($ Million)

Figure 21 Others: Global Orphan Drugs Market Value, 2022-2031 ($ Million)

Figure 22 Global Orphan Drugs Market Y-o-Y Growth, By Distribution Channel, 2022-2031 (%)

Figure 23 Hospital Pharmacies: Global Orphan Drugs Market Value, 2022-2031 ($ Million)

Figure 24 Retail Pharmacies: Global Orphan Drugs Market Value, 2022-2031 ($ Million)

Figure 25 Online Pharmacies: Global Orphan Drugs Market Value, 2022-2031 ($ Million)

Figure 26 Global Orphan Drugs Market Y-o-Y Growth, By Region, 2022-2031 (%)

Figure 27 North America Orphan Drugs Market Value, 2022-2031 ($ Million)

Figure 28 North America Orphan Drugs Market Share, By Product Type, 2022 &amp; 2031 (%)

Figure 29 North America Orphan Drugs Market Share, By Therapy Area, 2022 &amp; 2031 (%)

Figure 30 North America Orphan Drugs Market Share, By Distribution Channel, 2022 &amp; 2031 (%)

Figure 31 North America Orphan Drugs Market Share, By Country, 2022 &amp; 2031 (%)

Figure 32 South America Orphan Drugs Market Value, 2022-2031 ($ Million)

Figure 33 South America Orphan Drugs Market Share, By Product Type, 2022 &amp; 2031 (%)

Figure 34 South America Orphan Drugs Market Share, By Therapy Area, 2022 &amp; 2031 (%)

Figure 35 South America Orphan Drugs Market Share, By Distribution Channel, 2022 &amp; 2031 (%)

Figure 36 South America Orphan Drugs Market Share, By Country, 2022 &amp; 2031 (%)

Figure 37 Europe Orphan Drugs Market Value, 2022-2031 ($ Million)

Figure 38 Europe Orphan Drugs Market Share, By Product Type, 2022 &amp; 2031 (%)

Figure 39 Europe Orphan Drugs Market Share, By Therapy Area, 2022 &amp; 2031 (%)

Figure 40 Europe Orphan Drugs Market Share, By Distribution Channel, 2022 &amp; 2031 (%)

Figure 41 Europe Orphan Drugs Market Share, By Country, 2022 &amp; 2031 (%)

Figure 42 Asia-Pacific Orphan Drugs Market Value, 2022-2031 ($ Million)

Figure 43 Asia-Pacific Orphan Drugs Market Share, By Product Type, 2022 &amp; 2031 (%)

Figure 44 Asia-Pacific Orphan Drugs Market Share, By Therapy Area, 2022 &amp; 2031 (%)

Figure 45 Asia-Pacific Orphan Drugs Market Share, By Distribution Channel, 2022 &amp; 2031 (%)

Figure 46 Asia-Pacific Orphan Drugs Market Share, By Country, 2022 &amp; 2031 (%)

Figure 47 Middle East &amp; Africa Orphan Drugs Market Value, 2022-2031 ($ Million)

Figure 48 Middle East &amp; Africa Orphan Drugs Market Share, By Product Type, 2022 &amp; 2031 (%)

Figure 49 Middle East &amp; Africa Orphan Drugs Market Share, By Therapy Area, 2022 &amp; 2031 (%)

Figure 50 Middle East &amp; Africa Orphan Drugs Market Share, By Distribution Channel, 2022 &amp; 2031 (%)

Figure 51 AbbVie Inc.: Financials

Figure 52 Alexion Pharmaceuticals, Inc.: Financials

Figure 53 Bristol-Myers Squibb Company: Financials

Figure 54 Celgene Corporation: Financials

Figure 55 Johnson &amp; Johnson: Financials

Figure 56 Merck &amp; Co., Inc.: Financials

Figure 57 Novartis AG: Financials

Figure 58 Roche Holding AG: Financials

Figure 59 Sanofi SA: Financials

Figure 60 Shire plc: Financials